EP1221933A2 - Kosmetische zusammensetzung enthaltend ein steroid und eine fettlösliche uv-filtersubstanz - Google Patents

Kosmetische zusammensetzung enthaltend ein steroid und eine fettlösliche uv-filtersubstanz

Info

Publication number
EP1221933A2
EP1221933A2 EP00968050A EP00968050A EP1221933A2 EP 1221933 A2 EP1221933 A2 EP 1221933A2 EP 00968050 A EP00968050 A EP 00968050A EP 00968050 A EP00968050 A EP 00968050A EP 1221933 A2 EP1221933 A2 EP 1221933A2
Authority
EP
European Patent Office
Prior art keywords
composition according
filter
composition
derivatives
dhea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00968050A
Other languages
English (en)
French (fr)
Inventor
Francine Baldo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of EP1221933A2 publication Critical patent/EP1221933A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A61K8/585—Organosilicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • composition in particular cosmetic, containing a steroid and a liposoluble UV filter
  • the present invention relates to a composition containing, in a physiologically acceptable medium, at least one steroid chosen from: DHEA and / or a biological precursor and / or a metabolic derivative thereof, characterized in that it comprises in addition to at least one liposoluble UV filter. It also relates to its uses, and to a process for dissolving the aforementioned steroid by means of at least one liposoluble UV filter.
  • DHEA dehydroepiandrosterone
  • JP-07 196 467 keratinization of the epidermis
  • US Pat. No. 4,496,556 US Pat. No. 4,496,556
  • DHEA sulfate to treat various signs of aging such as wrinkles, loss of radiance of the skin and sagging skin
  • DHEA dissolves only with difficulty in aqueous and hydroalcoholic media, which limits its formulation in cosmetic or dermatological compositions applied topically or orally. It therefore tends to recrystallize or degrade. This results in a more or less significant loss of effectiveness of these compositions, depending on the degree of recrystallization and / or degradation, which goes against the objective sought.
  • this recrystallization or degradation can modify the overall stability of these compositions as well as their appearance, which can divert the user from them.
  • a subject of the present invention is therefore a composition containing, in a physiologically acceptable medium, at least one steroid chosen from DHEA and / or a biological precursor and / or a metabolic derivative thereof, characterized in that it comprises in addition to at least one liposoluble UV filter
  • It also relates to a process for the solubilization of at least one steroid chosen from DHEA and / or a biological precursor and / or a metabolic derivative thereof, comprising the step consisting in mixing said steroid with at least one filter.
  • the mixing can be carried out cold, at room temperature or hot, for example at 75 ° C., generally with stirring
  • DHEA has the following formula (I)
  • the DHEA which can be used according to the invention is for example available from the company AKZO NOBEL
  • biological precursors of DHEA is meant in particular ⁇ 5-pregnenoione and 17 ⁇ -hydroxy pregnenolone, without this list being limiting
  • metabolic derivatives of DHEA means in particular ⁇ 5-androstene-3,1-diol and ⁇ 4-androstene-3,17-d ⁇ one, as well as 7 ⁇ OH-DHEA, 7 ⁇ OH-DHEA and 7-keto-DHEA , without this list being limiting 7 ⁇ OH-DHEA is preferred for use in the present invention.
  • the composition according to the present invention contains, as a solubilizer for the steroids above, at least one liposoluble UV filter
  • salicylic acid derivatives such as homomenthyl salicylate, 2-ethylhexyl salicylate, triethanolamine salicylate, 4-isopropylbenzyl salicylate,
  • cmnamic acid derivatives such as isopentyl 4-methoxy cin ⁇ amate, 2-ethylhexyl 4-methoxy ci ⁇ namate, methyl dnsopropyl cinnamate, isoamyl 4-methoxy cinnamate, 4-methoxy diethanolamine cinnamate,
  • para-aminobenzoic acid derivatives such as 2-ethylhexyl p-dimethylaminobenzoate and glycerol p-aminobenzoate
  • salicylic acid derivatives which can be used according to the invention, more particularly will be chosen ' - homomenthyl salicylate (also known as homosalate), sold in particular under the name "KEMESTER HMS" by the company Witco II corresponds to the following formula
  • ⁇ , ⁇ '-phenylacrylate derivatives which can be used according to the present invention are preferably chosen from those corresponding to the following formula
  • R 7 and R ' 7 are in meta or para position and are chosen from hydrogen; a straight or branched chain C 1 -C 8 alkoxy radical; a straight or branched chain C 1 -C 4 alkyl radical;
  • - R 8 represents a C 1 -C 12 alkyl radical with a straight or branched chain
  • - R 9 represents a hydrogen atom or a -CN radical
  • ⁇ ⁇ '-d ⁇ phenylacrylate derivatives of formula (V) which can be used according to the present invention, more particularly preferred is 2-ethylhexyl diphenylacrylate, also called octocrylene, ⁇ -cyano- ⁇ . ⁇ ' lipophilic filter absorbing in UVB II is commercially available and sold in particular under the name "UVINUL N 539" by the company BASF II corresponds to the following formula
  • dibenzoylmethane derivatives it is particularly preferred to use 4- (tert-butyl) 4'-methoxy dibenzoylmethane, in particular that offered for sale under the trade name "PARSOL 1789" by the company GIVAUDAN
  • liposoluble benzophenone derivatives mention may be made of 2-hydroxy-4-methoxy-benzophenone, also called oxybenzone (benzophenone-3) as the product sold under the name UVINUL M40 by the company BASF
  • silicon derivatives of N-substituted Benzimidazolyl-Benzazoles or of Benzofuranyl-Benzazoles which are particularly suitable for use in the present invention are especially
  • the steroid concentration in the composition according to the invention is advantageously between 0.001% and 20% by weight, preferably between 0.01 and 10% by weight, more preferably between 0.1 and 3% by weight, relative to the total weight of the composition
  • the weight amount of liposoluble UV filter advantageously represents from 0.5% to 20%, better still, from 0.1 to 10%, of the total weight of the composition
  • composition according to the invention can be in all dosage forms normally used for topical application to the skin, in particular in the form of an oily solution, of an oil-in-water or water-in-oil or multiple emulsion. , a silicone emulsion, a microemulsion or nanoemulsion, an oily gel or a liquid, pasty or solid anhydrous product
  • This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. or a gel It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick. It can be used as a care product and / or as a make-up product. the skin, or as a hair product, for example as a shampoo or conditioner
  • the composition of the invention may also contain the adjuvants customary in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, soants, perfumes, fillers, pigments, odor absorbers and coloring matters
  • the amounts of these various adjuvants are those conventionally used in the fields considered, and for example from 0.01 to 20% of the total weight of the composition
  • These adjuvants depending on their nature, can be introduced in the fatty phase, in the aqueous phase, in the lipid vesicles and / or in the nanoparticles.
  • These adjuvants, as well as their concentrations, must be such that they do not harm the advantageous properties of the steroids according to the invention
  • the Sun Protection Factor which it is desired to impart to the composition according to the invention, it may advantageously contain one or more water-soluble UV filters
  • water-soluble UV filters examples include
  • the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition.
  • emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration
  • the emulsifier and the coemulsifier are preferably present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition
  • solubilizers based on 2-alkyl alkanols and their esters, oils and in particular oils.
  • mineral mineral
  • oils of vegetable origin oils of vegetable origin
  • lanolin oils of animal origin
  • synthetic oils perhydrosqualene
  • silicone oils cyclomethicone
  • fluorinated oils perfluoropolyethers
  • emulsifiers and coemulsifiers which can be used in the invention, there may be mentioned, for example, fatty acid and polyethylene glycol esters such as PEG-100 stearate, PEG-50 stearate and PEG-40 stearate, esters of fatty acid and polyol such as glyceryl stearate, sorbitan t ⁇ stearate and oxyethylenated sorbitan stearates available under the trade names Tween® 20 or Tween® 60, for example, and mixtures thereof
  • hydrophilic gelling agents mention may in particular be made of carboxy vinyl polymers (carbomer), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, may include modified clays such as bentones, metal salts of fatty acids and hydrophobic silica
  • composition according to the invention finds in particular an application in the prevention and treatment of the signs of chronological or actinic aging, as well as in the treatment of certain pathologies
  • the present invention therefore also relates to the cosmetic use of the composition mentioned above for preventing or treating the signs of chronological or actinic skin aging, in particular wrinkles and fine lines and / or sagging skin
  • composition according to the invention is intended for the prevention or treatment of actinic aging
  • present invention also relates to the use of the composition mentioned above for manufacturing a preparation intended to prevent or treat the signs of chronological or actinic skin aging.
  • composition according to the invention and / or the preparation obtained from it comprises an effective amount of steroid, sufficient to obtain the desired effect, and a physiologically acceptable medium.
  • compositions C1 to C3 are prepared as defined in Table 1
  • compositions C1 and C2 do not present DHEA crystals, while composition C3 already presents DHEA crystals, visible under a microscope under polarized light, after 24 hours of storage at 4 ° C or at room temperature
  • the above composition can be used as a care cream intended to fight against wrinkles and to prevent loss of firmness and elasticity of the skin.
  • the above composition can be used as an anti-aging day cream
  • This composition can be used to prevent or treat the signs of aging such as wrinkles and fine lines and sagging skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
EP00968050A 1999-10-13 2000-10-13 Kosmetische zusammensetzung enthaltend ein steroid und eine fettlösliche uv-filtersubstanz Withdrawn EP1221933A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9912773A FR2799645B1 (fr) 1999-10-13 1999-10-13 Utilisation de la dhea ou de ses precurseurs ou derives metaboliques comme depigmentant
FR9912773 1999-10-13
PCT/FR2000/002879 WO2001026618A2 (fr) 1999-10-13 2000-10-13 Composition, notamment cosmetique, renfermant un steroide et un filtre uv liposoluble

Publications (1)

Publication Number Publication Date
EP1221933A2 true EP1221933A2 (de) 2002-07-17

Family

ID=9550887

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00118605A Expired - Lifetime EP1092423B1 (de) 1999-10-13 2000-08-28 Verwendung von DHEA oder dessen Vorläufern und Metaboliten als Hautdepigmentierungsmittel
EP00968050A Withdrawn EP1221933A2 (de) 1999-10-13 2000-10-13 Kosmetische zusammensetzung enthaltend ein steroid und eine fettlösliche uv-filtersubstanz

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP00118605A Expired - Lifetime EP1092423B1 (de) 1999-10-13 2000-08-28 Verwendung von DHEA oder dessen Vorläufern und Metaboliten als Hautdepigmentierungsmittel

Country Status (10)

Country Link
US (2) US7351699B1 (de)
EP (2) EP1092423B1 (de)
JP (2) JP3803540B2 (de)
AT (1) ATE431176T1 (de)
AU (1) AU7801200A (de)
CA (2) CA2319916C (de)
DE (1) DE60042192D1 (de)
ES (1) ES2326406T3 (de)
FR (1) FR2799645B1 (de)
WO (1) WO2001026618A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2803514B1 (fr) * 1999-10-13 2004-05-21 Oreal Compostion, notamment cosmetique, renfermant un steroide et un filtre uv liposoluble
EP1269986B1 (de) * 2001-06-26 2009-02-25 L'oreal Zusammensetzungen, die eine wenig lösliche Verbindung und ein lipophiles Aminosäurederivat enthalten, und entsprechende Verwendungen und Verfahren
FR2826271B1 (fr) * 2001-06-26 2005-02-18 Oreal Composition a base de derives lipophiles d'acide amine
FR2826272B1 (fr) * 2001-06-26 2005-02-18 Oreal Composition contenant de la dhea ou un derive de la dhea et un derive lipophile d'acide amine
FR2828100B1 (fr) * 2001-08-02 2004-09-24 Galderma Res & Dev Composition de type emulsion inverse contenant de la dhea et/ou ses precurseurs ou derives, et ses utilisations en cosmetique et en dermatologie
WO2009088109A1 (en) * 2008-01-04 2009-07-16 Biospectrum, Inc. Composition for skin whitening containing diosgenin
EP2153815A1 (de) 2008-08-05 2010-02-17 Isdin S.A. Verwendung von harnstoffhaltigen Zusammensetzungen
EP2153814A1 (de) 2008-08-05 2010-02-17 Isdin S.A. Verwendung von harnstoffhaltigen Zusammensetzungen
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474763A (en) * 1982-07-07 1984-10-02 Lubowe Irwin I Skin preparation
JPH06271468A (ja) * 1993-01-20 1994-09-27 Hisamitsu Pharmaceut Co Inc ステロイド類溶解剤及びステロイド類を主剤とする外用液剤
JPH08337528A (ja) * 1995-06-15 1996-12-24 Advanced Sukin Res Kenkyusho:Kk メラニン生成抑制剤

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316033A (en) 1980-05-30 1982-02-16 General Electric Company Alkoxysilylbenzotriazoles
US4328346A (en) 1980-08-01 1982-05-04 General Electric Company Silane-functionalized ultraviolet screen precursors
DE3206398A1 (de) 1982-02-23 1983-09-01 Basf Ag, 6700 Ludwigshafen S-triazinderivate und ihre verwendung als lichtschutzmittel
FR2528420A1 (fr) 1982-06-15 1983-12-16 Oreal Nouveaux 3-benzylidene camphres, leur procede de preparation et leur utilisation pour la protection contre les rayons uv
US4542129A (en) * 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
US4496556A (en) 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
JPS60142908A (ja) 1983-12-29 1985-07-29 Kanebo Ltd 養毛化粧料
JPS60161912A (ja) * 1984-02-01 1985-08-23 Kanebo Ltd 皮膚化粧料
FR2581542B1 (fr) 1985-05-07 1988-02-19 Oreal Compositions topiques destinees au traitement de la peau a base de derives de l'acide salicylique
FR2635780B1 (fr) 1988-08-04 1990-12-14 Rhone Poulenc Chimie Diorganopolysiloxane a fonction benzotriazole
LU87394A1 (fr) 1988-11-22 1990-06-12 Oreal Sels de metaux polyvalents de derives sulfones du benzylidene-camphre et leur utilisation pour la protection de la peau contre le rayonnement ultraviolet
FR2642968B1 (fr) 1989-02-15 1991-06-07 Oreal Utilisation en cosmetique de diorganopolysiloxanes a fonction benzotriazole et nouvelles compositions cosmetiques contenant ces composes, destinees a la protection de la peau et des cheveux
EP0389377A1 (de) 1989-03-22 1990-09-26 Her Majesty In Right Of Canada As Represented By The National Research Council Of Canada Excretion von Proteinen von Hefezellen
JPH0674329B2 (ja) 1990-01-22 1994-09-21 信越化学工業株式会社 有機ケイ素化合物
IT1247973B (it) 1991-06-04 1995-01-05 Sigma Prod Chim Derivati di 1,3,5-triazina, loro preparazione e uso come filtri solari
FR2679140B1 (fr) 1991-07-19 1993-10-15 Oreal Composition cosmetique ou dermatologique depigmentante contenant des derives d'arbutoside.
IT1255729B (it) 1992-05-19 1995-11-15 Giuseppe Raspanti Derivati di s-triazina come agenti fotostabilizzanti
US5776438A (en) * 1992-06-26 1998-07-07 Shiseido Co., Ltd. External preparation
FR2695560B1 (fr) * 1992-09-17 1994-11-04 Oreal Composition cosmétique filtrante photostable contenant un filtre UV-A et un polymère filtre du type silicone benzotriazole.
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5607487A (en) * 1993-03-17 1997-03-04 Taylor; Leland T. Bottom feed - updraft gasification system
JP3428104B2 (ja) 1993-11-25 2003-07-22 株式会社資生堂 ベンゾフェノン誘導体、紫外線吸収剤及び皮膚外用剤
JPH07196467A (ja) * 1993-12-28 1995-08-01 Kanebo Ltd 表皮角質化促進剤
FR2714601B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition dépigmentante pour le traitement simultané des couches superficielles et profondes, son utilisation.
JP3521517B2 (ja) * 1994-12-28 2004-04-19 株式会社コーセー 皮膚外用剤
FR2729854A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation du sulfate de dehydroepi-androsterone dans une composition cosmetique ou dermatologique
US5523090A (en) * 1995-02-24 1996-06-04 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin treatment composition
EP0738510A3 (de) * 1995-04-20 2005-12-21 L'oreal Verwendung eines HMG-CoA-Reduktase Inhibitors als Hautalterungschutzmittel und als Anti-Aknemittel. Zusammensetzung enthaltend mindestens einen HMG-CoA-Reduktase Inhibitor und mindestens einen Wirkstoff mit abschuppenden Eigenschaften
FR2735686B1 (fr) * 1995-06-20 1997-09-26 Oreal Composition pour proteger et/ou lutter contre les taches et/ou le vieillissement de la peau, ses utilisations
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
FR2737410B1 (fr) 1995-07-31 1997-09-12 Oreal Utilisation de derives d'acide benzoique pour favoriser la desquamation de la peau ou stimuler le processus de renouvellement epidermique
US5736537A (en) * 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
FR2739556B1 (fr) * 1995-10-04 1998-01-09 Oreal Utilisation de carbohydrates pour favoriser la desquamation de la peau
WO1997013500A2 (en) 1995-10-12 1997-04-17 Supergen, Inc. LIPOSOME FORMULATIONS OF 5β STEROIDS
IT1283295B1 (it) 1996-03-22 1998-04-16 3V Sigma Spa Filtri solari
FR2759292B1 (fr) * 1997-02-10 2000-08-11 Cird Galderma Utilisation de retinoides en tant qu'agents induisant la pigmentation
FR2759370B1 (fr) 1997-02-12 2000-08-11 Oreal Nouveaux derives de l'acide salicylique et leur utilisation dans les compositions cosmetiques ou dermatologiques
FR2760362B1 (fr) * 1997-03-10 2000-08-11 Vitasterol Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles
FR2762839B1 (fr) 1997-04-30 2001-05-11 Oreal Nouveaux derives de l'acide salicylique et leur utilisation dans une composition cosmetique et/ou dermatologique
FR2765801B1 (fr) 1997-07-08 2003-04-11 Oreal Utilisation de monoesters d'arbutine comme agent depigmentant
US6149933A (en) * 1997-07-10 2000-11-21 Summa Rx Laboratories, Inc. Dietary supplement for promotion of healthy hair and pigment restoration
FR2767823B1 (fr) * 1997-08-27 1999-10-15 Oreal Composes derives d'aminophenol et leur utilisation en cosmetique
FR2770522B1 (fr) 1997-11-04 2000-03-10 Oreal Composes comportant un fragment iminophenol et leur utilisation en cosmetique
FR2772607B1 (fr) 1997-12-19 2000-02-04 Oreal Utilisation de derives amides d'amino phenol comme agents depigmentants
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
FR2777181A1 (fr) * 1998-04-10 1999-10-15 Lvmh Rech Compositions cosmetiques ou dermatologiques sous forme d'emulsions de type eau-dans-huile renfermant des cyclomethicones et des phospholipides et leur procede de preparation
FR2807323A1 (fr) * 2000-04-10 2001-10-12 Oreal Composition, notamment cosmetique, renfermant un steroide et un 2-alkyl alcanol ou un ester

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474763A (en) * 1982-07-07 1984-10-02 Lubowe Irwin I Skin preparation
JPH06271468A (ja) * 1993-01-20 1994-09-27 Hisamitsu Pharmaceut Co Inc ステロイド類溶解剤及びステロイド類を主剤とする外用液剤
JPH08337528A (ja) * 1995-06-15 1996-12-24 Advanced Sukin Res Kenkyusho:Kk メラニン生成抑制剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 018, no. 680 (C - 1291) 21 December 1994 (1994-12-21) *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 04 30 April 1997 (1997-04-30) *

Also Published As

Publication number Publication date
AU7801200A (en) 2001-04-23
EP1092423A3 (de) 2001-08-29
EP1092423B1 (de) 2009-05-13
ATE431176T1 (de) 2009-05-15
CA2355357A1 (fr) 2001-04-19
DE60042192D1 (de) 2009-06-25
CA2319916C (fr) 2010-02-23
US20080159971A1 (en) 2008-07-03
FR2799645A1 (fr) 2001-04-20
ES2326406T3 (es) 2009-10-09
FR2799645B1 (fr) 2004-04-30
WO2001026618A3 (fr) 2002-05-10
JP2001131072A (ja) 2001-05-15
EP1092423A2 (de) 2001-04-18
JP3803540B2 (ja) 2006-08-02
CA2319916A1 (fr) 2001-04-13
WO2001026618A2 (fr) 2001-04-19
JP2003511402A (ja) 2003-03-25
US7351699B1 (en) 2008-04-01

Similar Documents

Publication Publication Date Title
EP0648204B1 (de) Kosmetische anwendung von lipophiles derivates von aminodeoxyalditoles, diese enthaltende kosmetische zusammensetzungen und alkylcarbamates
EP1092422B1 (de) Mittel insbesondere für Kosmetika enthaltend eine Sapogenin
FR2782269A1 (fr) Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation
EP1269986B1 (de) Zusammensetzungen, die eine wenig lösliche Verbindung und ein lipophiles Aminosäurederivat enthalten, und entsprechende Verwendungen und Verfahren
CA2308793A1 (fr) Composition renfermant au moins un compose bicyclique aromatique et au moins un filtre solaire lipophile, et ses utilisations
FR2784294A1 (fr) Composition cosmetique et/ou dermatologique renfermant au moins un extrait de murier, au moins un extrait de scutellaire et au moins un derive d'acide salicylique
EP1252882B1 (de) Verfahren zur Erhöhung der Schwellentoleranz bei empfindlicher Haut
EP2193783A1 (de) Verwendung eines 2-Pyrrolidinon-4-Carboxy-Esters als Lösungsmittel in kosmetischen Zubereitungen; Zubereitungen enthaltend 2-Pyrrolidinon-4-Carboxy-Ester
CA2343426A1 (fr) Composition, notamment cosmetique, renfermant un steroide et un 2-alkyl alcanol ou un ester
EP1221933A2 (de) Kosmetische zusammensetzung enthaltend ein steroid und eine fettlösliche uv-filtersubstanz
EP1110538B1 (de) Aminophenolderivat enthaltendes Kosmetikum
EP2105165A2 (de) Kosmetische Zusammensetzung, enthaltend ein Derivat einer Imido-Percarboxysäure und einen N-acylierten Aminosäureester
FR2717078A1 (fr) Utilisation des acides sulfoniques comme agents antivieillissement dans une composition cosmétique ou dermatologique.
EP0835650A1 (de) Verwendung von Oxazolidinonderivaten als antipenetrante Mittel in einer kosmetischen und/oder dermatologischen Zubereitung
CA2181731C (fr) Composition filtrante a usage cosmetique ou dermatologique contenant un chelateur de fer
FR2782516A1 (fr) Procede de photostabilisation de filtres solaires derives du dibenzoylmethane, compositions cosmetiques filtrantes photostabilisees ainsi obtenues et leurs utilisation
EP0970690A1 (de) Kosmetische und/oder dermatologische Zusammensetzung die Salicylsäure-Derivate enthält und Verfahren zu ihrer Einführung in einer Wässerigen Zusammenstzung
FR2803514A1 (fr) Compostion, notamment cosmetique, renfermant un steroide et un filtre uv liposoluble
EP0625966B1 (de) Salze von urethanaminosäurederivaten mit primären aminen und ihre verwendung in kosmetischen zusammensetzungen
WO2003011244A1 (fr) Composition renfermant un steroide et un glycol
FR2815256A1 (fr) Composition, notamment cosmetique, comprenant au moins un derive de sapogenine et au moins un solubilisant du derive de sapogenine
FR2826273A1 (fr) Composition contenant des derives d'acide salicylique et des derives lipophiles d'acide amine
US20020172647A1 (en) Composition containing a steroid and a liposoluble UV filter
CA2305942A1 (fr) Composition renfermant au moins un compose bicyclique aromatique et au moins un 2-alkyl alcan-1-ol ou un ester, et ses utilisations
FR2826271A1 (fr) Composition a base de derives lipophiles d'acide amine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20021111

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060613